Felix Ratjen
Ratjen, F. A. (Felix A.)
Ratjen, Felix A.
VIAF ID: 24122393 (Personal)
Permalink: http://viaf.org/viaf/24122393
Preferred Forms
- 100 0 _ ‡a Felix Ratjen
-
-
-
- 100 1 _ ‡a Ratjen, F. A. ‡q (Felix A.)
- 100 1 _ ‡a Ratjen, Felix A.
4xx's: Alternate Name Forms (3)
Works
Title | Sources |
---|---|
Metabolites of nitric oxide in the lower respiratory tract of children | |
Microaspiration in infants with laryngomalacia. | |
MRI: the next frontier for cystic fibrosis clinicians? | |
Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. | |
Multiple breath nitrogen washout: a feasible alternative to mass spectrometry | |
Multitracer stable isotope quantification of arginase and nitric oxide synthase activity in a mouse model of pseudomonas lung infection. | |
Mycobacterium chelonae in a CF patient with anaplastic large cell lymphoma. | |
Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns | |
Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients | |
Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis | |
Nodular pulmonary vasculitis in a twelve-year-old boy. | |
Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue. | |
Paediatric bronchoscopy. | |
Paediatric respiratory disease: past, present and future. | |
Paediatrics in Vienna. | |
Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients. | |
Physiologic endpoints for clinical studies for cystic fibrosis. | |
Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. | |
Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. | |
Plastic bronchitis as an unusual cause of mucus plugging in cystic fibrosis | |
Preschool Multiple-Breath Washout Testing. An Official American Thoracic Society Technical Statement | |
The prevalence of asthma in Canadian children of South Asian descent | |
Progression of Lung Disease in Preschool Patients with Cystic Fibrosis. | |
Prospective evaluation of emerging bacteria in cystic fibrosis | |
Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis | |
Pulmonary artery hypertension: an underrated disease manifestation in cystic fibrosis? | |
Pulmonary exacerbations in CF patients with early lung disease. | |
Pulmonary function after early vs late lobectomy during childhood: a preliminary study. | |
[Pulmonary metabolism of nitric oxide (NO) in patients with cystic fibrosis] | |
Rapid pulmonary delivery of inhaled tobramycin for Pseudomonas infection in cystic fibrosis: a pilot project | |
[Recommendations for the diagnosis, therapy and prevention of pneumonia in the immunocompromised host] | |
Reduced lung function in cystic fibrosis: a primary or secondary phenotype? | |
Reliability and validity of the habitual activity estimation scale (HAES) in patients with cystic fibrosis. | |
The Remaining Barriers to Normalcy in CF: Advances in Assessment of CF Lung Disease | |
Respiratory medicines for children: current evidence, unlicensed use and research priorities | |
Response to letter | |
Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients. | |
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in children with cystic fibrosis. | |
Single-lung transplantation in a patient with cystic fibrosis and an asymmetric thorax | |
Skeletal muscle metabolism in cystic fibrosis and primary ciliary dyskinesia | |
Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis | |
Sputum induction in routine clinical care of children with cystic fibrosis | |
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. | |
Standardy opieki Europejskiego Towarzystwa Mukowiscydozy: wytyczne i najlepsze praktyki | |
Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. | |
Surfactant in children with malignancies, immunosuppression, fever and pulmonary infiltrates. | |
Surfactant protein a in cystic fibrosis: supratrimeric structure and pulmonary outcome | |
Symptomatic liver involvement in neonatal hereditary hemorrhagic telangiectasia | |
Task force on chronic interstitial lung disease in immunocompetent children. | |
Tiotropium Respimat in cystic fibrosis: Phase 3 and Pooled phase 2/3 randomized trials | |
Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. | |
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial | |
Tuberculoma of the pons | |
Update in cystic fibrosis 2008. | |
Utility of contrast echocardiography for pulmonary arteriovenous malformation screening in pediatric hereditary hemorrhagic telangiectasia | |
Utility of MDCT MIP Postprocessing Reconstruction Images in Children With Hereditary Hemorrhagic Telangiectasia | |
Validation of multiple breath washout devices. | |
Variability of dynamic compliance measurements in spontaneously breathing and ventilated newborn infants | |
Ventilation inhomogeneity in infants with recurrent wheezing | |
What's new in CF airway inflammation: an update. |